Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

CNS Drugs

Volumn 30, Issue 9, 2016, Pages 877-888

  Perlemuter, Gabriel ^a,b,c   Cacoub, Patrice ^d,e,f,g   Valla, Dominique ^h,i   Guyader, Dominique ^j,k   Saba, Barbara ^l   Batailler, Cécile ^l   Moore, Kevin ^m  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Universite Paris Sud   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e Inflammation Immunopathology Biotherapy Department (DHU i2B)   (France)

^f Sorbonne Université   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^j PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ DE RENNES 1   (France)

^l IRIS Institut de Recherches Internationales Servier   (France)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; ACETAMIDE DERIVATIVE; AMINOTRANSFERASE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; DRUG SAFETY; FEMALE; FREQUENCY; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; LIVER; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; ENZYMOLOGY; META ANALYSIS; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TOXIC HEPATITIS;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSAMINASES;

EID: 84976292093     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0351-6     Document Type: Article

References (50)

1. European Medicines Agency. Agomelatine. Summary of product characteristics. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf. Accessed 2 June 2016.
2. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19(5):271–80.
3. Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology. 2004;127(6):1847–9.
4. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C, Agomelatine Bipolar Study Group. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007;9(6):628–35. doi:10.1111/j.1399-5618.2007.00507.x.
5. Corruble E, de Bodinat C, Belaidi C, Goodwin GM, Agomelatine study group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16(10):2219–34. doi:10.1017/S1461145713000679.
6. Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kasper S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013;18(3):163–70. doi:10.1017/S1092852913000060.
7. Goodwin GM, Boyer P, Emsley R, Rouillon F, de Bodinat C. Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. Int Clin Psychopharmacol. 2013;28(1):20–8. doi:10.1097/YIC.0b013e32835b0814.
8. Goodwin GM, Emsley R, Rembry S, Rouillon F, Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(8):1128–37. doi:10.4088/JCP.08m04548.
9. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol. 2010;25(6):305–14. doi:10.1097/YIC.0b013e32833a86aa.
10. Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry. 2013;74(6):587–94. doi:10.4088/JCP.12m08250.
11. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71(2):109–20. doi:10.4088/JCP.09m05347blu.
12. Kennedy SH, Avedisova A, Gimenez-Montesinos N, Belaidi C, de Bodinat C, Agomelatine Study Group. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder. Eur Neuropsychopharmacol. 2014;24(4):553–63. doi:10.1016/j.euroneuro.2014.01.006.
13. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16(2):93–100. doi:10.1016/j.euroneuro.2005.09.002.
14. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28(3):329–33. doi:10.1097/JCP.0b013e318172b48c.
15. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24(6):479–99. doi:10.2165/11534420-000000000-00000.
16. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68(11):1723–32.
17. Loo H, Hale A, D’Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17(5):239–47.
18. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10(5):661–73. doi:10.1017/S1461145707007766.
19. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology. 2007;190(4):575–9. doi:10.1007/s00213-006-0645-3.
20. Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10(5):691–6. doi:10.1017/S1461145707007754.
21. Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011;26(5):252–62. doi:10.1097/YIC.0b013e328349b117.
22. Shu L, Sulaiman AH, Huang YS, Fones Soon Leng C, Crutel VS, Kim YS. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25–50 mg or fluoxetine 20–40 mg in Asian out-patients with major depressive disorder. Asian J Psychiatry. 2014;8:26–32. doi:10.1016/j.ajp.2013.09.009.
23. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010;71(5):616–26. doi:10.4088/JCP.09m05471blu.
24. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(7):1002–8. doi:10.4088/JCP.11m07493.
25. Stein DJ, Ahokas A, Marquez MS, Hoschl C, Oh KS, Jarema M, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry. 2014;75(4):362–8. doi:10.4088/JCP.13m08433.
26. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):561–6. doi:10.1097/JCP.0b013e318184ff5b.
27. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013;28(2):151–9. doi:10.1002/hup.2294.
28. Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry. 2016;208(1):78–86. doi:10.1192/bjp.bp.114.147587.
29. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30(2):135–44. doi:10.1097/JCP.0b013e3181d420a7.
30. Delaveau P, Jabourian M, Lemogne C, Allaili N, Choucha W, Girault N, et al. Antidepressant short-term and long-term brain effects during self-referential processing in major depression. Psychiatry Res. 2016;247:17–24. doi:10.1016/j.pscychresns.2015.11.007.
31. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. 2009. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf. Accessed 23 May 2016.
32. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014;171(4):404–15.
33. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin. 2007;23(1):175–84.
34. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16(3 Suppl 2):54S–9S (discussion 9S–61S).
35. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187–95.
36. Lucena MI, Andrade RJ, Kaplowitz N, Garcia-Cortes M, Fernandez MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001–9.
37. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29(4):337–47.
38. Rosenzweig P, Miget N, Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol. 1999;48(1):19–23.
39. Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab. 2007;3(6):458–69.
40. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16(23):3041–53.
41. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003–9.
42. Reuben A. Hy’s law. Hepatology. 2004;39(2):574–8.
43. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32(1):3–13.
44. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52.
45. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol. 2005;33(1):1–5.
46. Gruz F, Raffa S, Santucci C, Papale RM, Videla MG, Fernandez MG, et al. Agomelatine: fulminant liver failure in a patient with fatty liver [in Spanish]. Gastroenterol Hepatol. 2014;37(2):92–4. doi:10.1016/j.gastrohep.2013.04.008.
47. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734–50.
48. Cooper GL. The safety of fluoxetine–an update. Br J Psychiatry Suppl. 1988;3:77–86.
49. DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother. 2007;41(7):1201–11. doi:10.1345/aph.1K114.
50. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888. doi:10.1136/bmj.g1888.